Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 734.79K | Year: 1997
A synthetic peptide, DP-178, representing a discrete region of the HIV fusion protein, gp4l, effectvirus-mediated cell to cell fusion as well as de novo virus infection of T-cells (2). DP-178 has beeselectively to soluble forms of HIV-1 gp41 from which it was derived (4). While DP-178 is promisingtherapeutic, it may exhibit a limited delivery profile characteristic of peptide therapeutics. Theresmall molecule mimic of DP-178, by exploiting the selective binding of this peptide to soluble formsobjectives are to discover and develop a novel class of antivirals for the treatment of HIV infectiodevelop a high through-put biochemical screen based on the binding of DP-178 to gp41 analogs as a finew antiviral leads. Our specific aims are (1) to develop an antibody-based biochemical binding assathrough-put screen; (2) to develop a direct binding biochemical assay suitable as a high through-putcell-based gp41 binding and fusion assay suitable as a high through-put screen; (4) to identify sourscreening.
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 99.93K | Year: 1996
Trimeris | Date: 1996-01-11
pharmaceutical preparations for treatment of viruses and dermatological disorders. medical devices, namely, syringes, test kits consisting primarily of microtitre plates with peptide chemistries for drug discovery screens to discover or create new pharmaceutical compounds, drug applicators for administering drugs in the nature of self-contained injection devices and constant infusion pumps. drug testing featuring the use of computer-aided analysis of data.